Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
The use of omalizumab in asthma.
TL;DR: Add-on omalizumab is indicated for the treatment of patients with inadequately controlled moderate-to-severe and severe (EU label) persistent allergic asthma despite treatment with high-dose inhaled corticosteroids plus a long-acting beta2-agonist.
Journal ArticleDOI
Usefulness of omalizumab in ten patients with severe occupational asthma.
François Lavaud,Philippe Bonniaud,Jean-Charles Dalphin,Christophe Leroyer,Dominique Muller,R. Tannous,G. Mangiapan,F. de Blay +7 more
TL;DR: The management of severe occupational asthma remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job.
Journal ArticleDOI
Omalizumab Attenuates Airway Inflammation and Interleukin-5 Production by Mononuclear Cells in Patients with Severe Allergic Asthma
Yotaro Takaku,Tomoyuki Soma,Fuyumi Nishihara,Kazuyuki Nakagome,Takehito Kobayashi,Koichi Hagiwara,Minoru Kanazawa,Makoto Nagata +7 more
TL;DR: Omalizumab exerts inhibitory effects on airway inflammation in Japanese patients with severe allergic asthma and attenuates production of IL-5 by PBMCs stimulated with both a specific allergen and a nonspecific activator.
Journal ArticleDOI
Asthma treatment: 'magic bullets which seek their own targets'.
TL;DR: Although with some restrictions, represented by the high costs and the limitation of its use only to a specific subset of patients affected by allergic asthma, at present anti‐IgE appear to be the only ‘magic bullet’ for the treatment of allergic asthma.
Journal ArticleDOI
Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) Asthma
Stefan Zielen,A Lieb,Stephan De la Motte,Frank Wagner,Jan G.R. de Monchy,Rainard Fuhr,Clara Munzu,Stephan Koehne-Voss,Gilles-Jacques Riviere,Guenther Kaiser,Veit J. Erpenbeck +10 more
TL;DR: Omalizumab blocked early asthmatic responses over a broad range of IgE/body weight combinations and completely suppressed FENO increases after ABP in both groups.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.